TY - JOUR T1 - Fusion of the Genes <em>WWTR1</em> and <em>FOSB</em> in Pseudomyogenic Hemangioendothelioma JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 293 LP - 298 DO - 10.21873/cgp.20134 VL - 16 IS - 4 AU - IOANNIS PANAGOPOULOS AU - INGVILD LOBMAIER AU - LUDMILA GORUNOVA AU - SVERRE HEIM Y1 - 2019/07/01 UR - http://cgp.iiarjournals.org/content/16/4/293.abstract N2 - Background/Aim: Pseudomyogenic hemangioendothelioma is a rare endothelial tumor. Previous genetic investigations have shown that the tumors carry either a SERPINE1-FOSB or an ACTB-FOSB fusion gene. The aim of the study was to identify FOSB fusions linked with pseudomyogenic hemangioendothelioma. Materials and Methods: RNA sequencing, reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing analyses were performed on a pseudomyogenic hemangioendothelioma. Results: An in-frame fusion was found between exon 4 of WWTR1 from 3q25 and exon 2 of FOSB from 19q13. The fusion gene not only places FOSB under the control of the WWTR1 promoter, but is predicted to encode a chimeric WWTR1-FOSB transcription factor. Conclusion: FOSB may be fused with SERPINE1, ACTB, or WWTR1 in pseudomyogenic hemangioendotheliomas. The resulting overexpression of FOSB fusion is a potentially useful marker that could be helpful in the diagnosis of these tumors. ER -